Background
==========

Pheochromocytoma (PCC) is a rare neoplasm that derives from the chromaffin cells of the adrenal medulla and produces and secretes catecholamines. Tumours that develop from the sympathetic ganglia are referred to as paragangliomas (PGLs). Genetic alterations are reportedly responsible for approximately 10% of all PCCs. A recent study, however, revealed that up to 40% of PCC/PGL patients carry a germline mutation in susceptibility genes such as *RET*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *VHL*, *NF1*, *TMEM127* and *MAX* ([@bib1]). Therefore, the European Society of Endocrinology as well as the Endocrine Society recommend that genetic testing be considered for all patients with PCC/PGL, especially in cases with a positive family history; syndromic features; and multifocal, bilateral or metastatic disease ([@bib2], [@bib3]). The *TMEM127* gene was recently identified as a new PCC susceptibility gene ([@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9]). Only two independent Japanese families have been reported to have mutation in *TMEM127* ([@bib10]). Here we report a case of PCC in which a novel germline variant was detected in the *TMEM 127* gene.

Case presentation
=================

A 42-year-old man (weight 60 kg, height 160 cm) was referred to our hospital for further examination of a left adrenal mass incidentally discovered by ultrasonography during a routine physical check-up. He had never been diagnosed with hypertension, but on admission his blood pressure was 141/89 mmHg with a regular pulse (76/min). He had no abnormal physical findings. His father underwent a unilateral adrenalectomy due to PCC at the age of 65, and was being evaluated for residual or contralateral adrenal PCC.

Investigation
=============

Laboratory tests revealed an adrenaline-dominant increase in the plasma and urinary catecholamine concentrations and their metabolites as follows: adrenaline 522 pg/mL (\<100 pg/mL), noradrenaline 215 pg/mL (100--450 pg/mL), dopamine 8 pg/mL (\<20 pg/mL), urinary metanephrine 3.61 mg/day (0.04--0.19), and urinary normetanephrine 0.40 mg/day (0.09--0.33). Abdominal computed tomography (CT) revealed a left adrenal mass approximately 6 cm × 4 cm in size ([Fig. 1A](#fig1){ref-type="fig"} and [B](#fig1){ref-type="fig"}). In T2-weighted magnetic resonance imaging (MRI) and diffusion-weighted images (DWI), the tumour exhibited relatively strong high signal intensity, and a cystic region was observed inside the tumour ([Fig. 1C](#fig1){ref-type="fig"} and [D](#fig1){ref-type="fig"}). ^123^I-Metaiodobenzylguanidine (MIBG) scintigraphy revealed positive uptake not only in the region corresponding to the left adrenal mass lesion, but also on the right adrenal gland, which did not appear abnormal by either CT or MRI ([Fig. 2](#fig2){ref-type="fig"}). Based on both his family history and putative bilateral PCC-based ^123^I-MIBG imaging studies, genetic alterations were suspected. A genetic analysis was performed for *RET*, *VHL*, *SDHB*, *SDHD*, *MAX* and *TMEM127* under the patient's informed consent. A novel missense variant (c.119C \> T, p.S40F) was identified in the *TMEM127* gene ([Fig. 3](#fig3){ref-type="fig"}). All three *in silico* analyses (Mutation Taster, SIFT, and PolyPhen-2) predicted that this variant would produce a functional alteration. Figure 1Imaging analysis of the adrenal mass. A coronal section (A) and sagittal section (B) on CT showed a mass with heterogeneous intensity in the left adrenal gland. T1-weighted (C) and T2-weighted (D) MRI. The left adrenal mass showed high signal intensity in T2-weighted MRI. Figure 2^123^I-MIBG imaging (A) and SPECT imaging (B) of the adrenal masses. In addition to the left adrenal mass, significant ^123^I-MIBG uptake was observed in the right adrenal gland (arrows). Figure 3Histopathologic findings of the surgically removed left adrenal tumour. The lower magnification (A), and higher magnification (B) of haematoxylin and eosin stain. (C) Immunohistochemistry for chromogranin A: The brown staining indicates expression of chromogranin A in the tumour cells. Ki67 labelling index was low (approximately 1%) (D).

Treatment
=========

Although bilateral PCC was suspected, laparoscopic unilateral adrenalectomy of the left adrenal gland, which was thought to be the dominant side, was performed.

Outcome and follow-up
=====================

After surgery, his blood pressure normalized and the plasma and urinary catecholamine concentrations and their metabolites were within the normal range (plasma adrenaline \<5 pg/mL, plasma noradrenaline 130 pg/mL, plasma dopamine \<5 pg/mL, urinary metanephrine 0.1 mg/day and normetanephrine 0.23 mg/day). He has been well without recurrence for 1 year since the surgery.

The weight of the left glands with the mass was 89.5 g (6.2 × 4.0 × 2.6 cm). Histologic findings confirmed the diagnosis of PCC and the PCC of the adrenal gland scaled score (PASS score) was 2, suggesting a tumour with low likelihood of malignancy (Fig. 3)

Loss of heterozygosity (LOH) of the *TMEM127* variant was confirmed by sequencing analysis of the surgically removed tumour, suggesting the functional significance of this variant ([Fig. 4](#fig4){ref-type="fig"} middle panel). Although hereditary PCC in the father of this patient was suspected, he was not willing to undergo genetic testing for *TMEM127*. Figure 4An electrophenogram around codon 40 in the *TMEM127* gene in the peripheral blood DNA of the patient (upper panel), in the surgically removed tumour tissue (middle panel), and a normal control (lower panel). The peripheral blood DNA of the patient showed c.119C \> T in heterozygosity. The tumour tissue DNA showed loss of the wild-type C allele, indicating LOH.

Discussion
==========

*TMEM127* is a negative regulator of mammalian target of rapamycin effector proteins, which promote cell growth and protein translation. TMEM127 protein interacts with several effector proteins of receptor kinase intracellular signalling pathways, and eventually acts as tumour suppressor protein ([@bib4]). As TMEM127 acts as tumour suppressor, a second hit is necessary to develop the tumourigenesis in *TMEM127* mutated PCC/PGL patients. In the present case, we identified a novel *TMEM127* gene missense variant (c.119C \> T, p.S40F). This variant was classified as likely pathogenic by ACMG guideline ([@bib11]). Although genetic heredity was not confirmed due to the father's unwillingness to undergo genetic testing, *in silico* analysis and the demonstration of the second hit of this variant (i.e., LOH) strongly suggest that this variant affects the function of the *TMEM127* protein.

The present case suggested two important clinical issues regarding the characteristics and management of PCC with a *TMEM127* mutation. First, in addition to reporting a novel pathogenic variant of *TMEM127*, we describe a rare case of *TMEM127*-related familial PCC. This is the third Japanese family of *TMEM127*-mediated PCC with distinct variant from the previous two families ([@bib10]). In a recent study of 990 individuals with PCC/PGL, screening identified potentially pathogenic *TMEM127* mutations in only 20 patients (2%) presenting with PCC, 5 of whom had a family history of PCC ([@bib12]). A previous study revealed that family history is confirmed in approximately 15% of cases ([@bib12]). In another study of 151 individuals from a 6-generation family carrying a *TMEM127* germline mutation, the median age was 43 years, and the cumulative penetrance rate was 0% at 0--20 years, 3% at 21--30 years, 15% at 31--40 years, 24% at 41--50 years and 32% at 51--65 years ([@bib13]). These studies suggest that the penetrance of *TMEM127*-related PCC/PGL is relatively low. The present case may provide additional information on the penetrance of *TMEM127-*related PCC/PGL. According to the recommendations of the Endocrine Society, mutation carriers should undergo annual clinical surveillance ([@bib2]). The proband in the present case has two sons, ages 7 and 9 years, and thus we recommend careful genetic counselling for their health management.

Second, unilateral adrenalectomy may be selected as the initial surgery in such cases. *TMEM127*-mediated PCC is bilateral in 30% of cases ([@bib12]). In the present case, although CT and MRI did not support bilateral PCC, findings from the ^123^I-MIBG study suggested bilateral lesions. Therefore, we diagnosed the patient with bilateral PCC with a *TMEM127* variant. In the present case, 1 year after unilateral adrenalectomy, the patient's blood pressure was normal and plasma and urinary catecholamine concentrations and their metabolites levels were in the normal range. Although uptake to right adrenal gland could have been a false positive finding, we speculate that the right adrenal PCC was too small to detect on CT or MRI, and to reveal clinical symptoms and biochemical alterations. This lesion, however, should continue to be carefully observed.

In conclusion, we report a case of familial and possibly bilateral PCC with a novel *TMEM127* variant, and unilateral adrenalectomy for the dominant tumour provided clinical and biochemical remission of PCC for at least 1 year.
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